LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Avantor, Inc. ("Avantor†or the "Company†) (NYSE: AVTR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AVANTOR, INC. (AVTR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On April 25, 2025, Avantor released its first quarter 2025 financial results, m. ...

SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Stride, Inc. (NYSE: LRN) focused on whether Stride and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Stride investigation or if you are a Stride investor who suffered a loss and would like to learn more, you ...

Core Points - A class action securities lawsuit has been filed against Cytokinetics, Incorporated, alleging securities fraud affecting investors between December 27, 2023, and May 6, 2025 [2][3] - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, particularly concerning the expected FDA approval timeline [3] - The company allegedly failed to disclose significant risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) from the NDA submission, which could delay the regulatory process [3] Case Details - Defendants represented that FDA approval for aficamten was expected in the second half of 2025, based on a PDUFA date of September 26, 2025 [3] - It was revealed during an earnings call on May 6, 2025, that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [3] - As a result of these misleading statements, investors purchased Cytokinetics' common stock at inflated prices and incurred significant losses when the truth was disclosed [3] Next Steps - Investors who suffered losses in Cytokinetics during the relevant period have until November 17, 2025, to request to be appointed as lead plaintiff in the lawsuit [4] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4] Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5]

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage completely [2] - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop of 83.2% from $6.03 to $1.02 per share in one day [2] Case Details - The lawsuit seeks to recover losses for investors who were adversely affected by the alleged fraud [1] - The primary endpoint that was not met involved the change from baseline in mean daily OSC dose at week 48 [2] - Following the disappointing results, aTyr plans to engage with the FDA to determine the next steps [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Marex Group plc is facing a class action securities lawsuit due to alleged securities fraud that occurred between May 16, 2024, and August 5, 2025, which has adversely affected investors [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the improper inflation of cash flow, revenues, assets, and profits in the Market Making segment through off-book intercompany transactions [2]. - As a result of these actions, the positive statements made by the defendants about the Company's business and prospects were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified time frame have until December 8, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has extensive expertise in complex securities litigation, with a team of over 70 employees [4].

Core Viewpoint - The Avantor class action lawsuit alleges that the company and its executives misrepresented the competitive positioning and financial health of Avantor, leading to significant stock price declines following disappointing financial results [1][3][4][5][6]. Group 1: Allegations and Financial Performance - The lawsuit claims that Avantor failed to disclose its weaker competitive positioning and the negative impact of increased competition during the class period [3]. - On April 25, 2025, Avantor reported weak first-quarter results, with the CFO admitting to the impact of increased competition, resulting in a stock price drop of over 16% [4]. - On August 1, 2025, the company reported disappointing second-quarter results and reduced its full-year guidance, leading to a further stock price decline of more than 15% [5]. - On October 29, 2025, Avantor announced weak third-quarter results, including a 5% decrease in organic revenue growth, causing the stock price to fall by over 23% [6]. Group 2: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Avantor common stock during the class period to seek appointment as lead plaintiff in the lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm of their choice for litigation [7]. Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [8]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [8].

Core Viewpoint - The Avantor class action lawsuit alleges that the company and its executives misrepresented the competitive positioning and financial health of Avantor, leading to significant stock price declines following disappointing financial results [3][4][5][6]. Group 1: Lawsuit Details - The lawsuit is titled "Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc." and is filed in the Eastern District of Pennsylvania [1]. - It seeks to represent purchasers of Avantor common stock and claims violations of the Securities Exchange Act of 1934 [1]. - The lead plaintiff motions must be filed by December 29, 2025 [2]. Group 2: Allegations of Misrepresentation - The lawsuit alleges that Avantor's competitive positioning was weaker than publicly represented, and the company faced negative impacts from increased competition [3]. - On April 25, 2025, Avantor reported weak first-quarter results, leading to a stock price drop of over 16% [4]. - On August 1, 2025, the company reported disappointing second-quarter results and reduced its full-year guidance, causing a further stock price decline of over 15% [5]. - On October 29, 2025, Avantor announced weak third-quarter results, including a 5% decrease in organic revenue growth, resulting in a stock price drop of over 23% [6]. Group 3: Company Background - Avantor provides mission-critical products and services to various sectors, including biopharma, healthcare, education, and advanced technologies [3].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [3]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted [3]. - There was an increased risk that customers would be advised to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 15, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's status [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3][6]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4].